Observed arrival · 2026-08-22
Peptide Evidence Watch Separates Regulatory Signals from Regulatory Reality
A U.S.-focused peptide evidence and regulatory intelligence desk tracking FDA and Health Canada actions for consumers and professional operators.
Why it surfaced
Its sample brief makes a useful distinction between an FDA proposal, an advisory committee review, and a final agency action, using BPC-157 as the test case. The site attaches primary sources to each status and turns them into concrete verification steps for clinics, pharmacies, labs, advisors, and investors.
A U.S.-focused peptide evidence and regulatory intelligence desk tracking FDA and Health Canada actions for consumers and professional operators.
Observed signals
Read the marks
Editorial observations of this landing page, not a rating.
One card from the complete issue